Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig vs Pembrolizumab in 1L Metastatic NSCLC (eVOLVE-Lung02)
NCT05984277Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2023
- Primary completion
- Aug 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of volrustomig in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Oct 2023; status: active, not recruiting.
02
Drugs
volrustomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05984277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984277.